Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 6 of 12, showing 5 Applications out of 60 total, starting on record 26, ending on 30

# Protocol No Study Title Investigator(s) & Site(s) Application Status

26.

ECCT/15/12/02   The Evidence for Contraceptive options and HIV Outcomes (ECHO) Trial
    A Multi Centre, Open label, Randomized Clinical Trial, Comparing HIV incidence and Contraceptive Benefits in Women using Depot Medroxyprogesterone Acetate, Levernogestrel (LNG) implant and Copper Intrauterine Devices (IUD).   Short Title : The Evidence for Contraceptive options and HIV Outcomes (ECHO) Trial   
Principal Investigator(s)
1. Prof Elizabeth Anne Bukusi
Site(s) in Kenya
KEMRI-RCTP Study center , Lumumba
 
Trial Status Analysing
Protocol Date 30-01-2015
View

27.

ECCT/15/08/01   Rifapentine During Intensive Phase TB Treatment
     Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis: a randomized, open-label, controlled, phase 3 clinical trial   
Principal Investigator(s)
1. Elisha Ochieng Okeyo
Site(s) in Kenya
KEMRICDC, KISUMU, KENYA
 
Trial Status In follow-up
Protocol Date 24-11-2014
View

28.

ECCT/15/06/01  
    Pyronaridine-artesunate and artemether-lumefantrine for the treatment of paediatric uncomplicated falciparum malaria in Western Kenya   
Principal Investigator(s)
1. Patrick Sawa
Site(s) in Kenya
St. Judes Clinic, ICIPE
 
Trial Status Recruiting
Protocol Date 13-04-2015
View

29.

ECCT/15/03/01   A phase III, non-inferiority trial using Carbetocin room temperature stable (RTS) for the prevention of postpartum haemorrhage during the third stage of labour in women delivering
    A phase III, randomized, double-blind, active, controlled, multinational, multicentre,  non-inferiority trial using Carbetocin room temperature stable (RTS) for the prevention of postpartum haemorrhage during the third stage of labour in women delivering vaginally.   
Principal Investigator(s)
1. Zahida Qureshi
Site(s) in Kenya
Kenyatta National Hospital
 
Trial Status Completed
Protocol Date 08-12-2014
View

30.

ECCT/15/06/03   DolutegrAvir With NRTIs as second-line treatment (DAWNING)
    A Phase 3b, randomised, open-label study of the antiviral activity and safety of dolutegravir compared to lopinavir/ritonavir both administered with dual nucleoside reverse transcriptase inhibitor therapy in HIV-1 infected adult subjects with treatment failure on first line therapy   
Principal Investigator(s)
1. Dr. Evans Inyangala Amukoye
2. Dr. Maricianah Atieno Onono
Site(s) in Kenya
1. Center for Respiratory Diseases Research, CRDR, KEMRI, Nairobi (Nairobi City county)
2. KEMRI-Research Care and Training Program (RCTP), Family AIDS Care and Education Services (FACES), Lumumba health centre (Kisumu county)
 
Trial Status Completed
Protocol Date 30-04-2014
View